Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

75.54 -0.21 (-0.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

7 Under-the-Radar Stocks With 100% Upside Potential ↗

October 17, 2022

If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully.

Via InvestorPlace

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

October 11, 2022

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics Return On Capital Employed Overview ↗

August 11, 2022

Via Benzinga

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗

July 26, 2022

IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.

Via Investor's Business Daily

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗

July 15, 2022

The group has several commonalities, including strong ratings and promising charts.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗

August 01, 2022

Upgrades

Via Benzinga

3 Biotech Stocks Outperforming a Bear Market ↗

July 15, 2022

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.

Via InvestorPlace

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

July 13, 2022

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 11, 2022

On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.

Via Investor's Business Daily

Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗

July 11, 2022

Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating.

Via Investor's Business Daily

Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗

July 08, 2022

The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

July 08, 2022

Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier.

Via Investor's Business Daily

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗

July 05, 2022

Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.

Via Investor's Business Daily

Kura Oncology Stock Scores Rising Relative Strength ↗

June 30, 2022

On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.

Via Investor's Business Daily

Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗

June 30, 2022

Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study ↗

June 29, 2022

Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Via Benzinga

Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

June 28, 2022

Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.

Via Investor's Business Daily

Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling ↗

June 28, 2022

Corcept makes a Cushing's drug that, by another name, causes medical abortion.

Via Investor's Business Daily

Corcept Stock Near Buy Point; Strength Rating Jumps To 91 ↗

June 23, 2022

The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.

Via Investor's Business Daily

Top Mid-Cap Stocks: Trading Opportunities For Next Week - Sunday, June 19 ↗

June 19, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some mid-cap stock opportunities by analyzing...

Via Talk Markets

Corcept Update

May 18, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

NASDAQ:CORT Investor Alert: Investigation over Potential Wrongdoing at Corcept Therapeutics Incorporated ↗

May 09, 2022

San Diego, CA -- (SBWIRE) -- 05/09/2022 -- Certain directors of Corcept Therapeutics Incorporated are under investigation over potential breaches of fiduciary duties.

Via SBWire

Preview: Corcept Therapeutics's Earnings ↗

May 04, 2022

Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Corcept Shareholder Notice

April 20, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shareholder Alert: Update on Lawsuit Against Corcept Therapeutics ↗

March 22, 2022

San Diego, CA -- (SBWIRE) -- 03/22/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Corcept Therapeutics Incorporated (NASDAQ:CORT)...

Via SBWire

Corcept Therapeutics's Return On Capital Employed Overview ↗

February 16, 2022

According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million...

Via Benzinga

Recap: Corcept Therapeutics Q4 Earnings ↗

February 15, 2022

Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

Earnings Scheduled For February 15, 2022 ↗

February 15, 2022

Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

All News about Corcept Therapeutics Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today